» Articles » PMID: 26919294

Molecular Identification and Echinocandin Susceptibility of Candida Parapsilosis Complex Bloodstream Isolates in Italy, 2007-2014

Overview
Journal PLoS One
Date 2016 Feb 27
PMID 26919294
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

The Candida parapsilosis group encompasses three species: C. parapsilosis, C. orthopsilosis, and C. metapsilosis. Here, we describe the incidence and echinocandin susceptibility profile of bloodstream isolates of these three species collected from patients admitted to an Italian university hospital from 2007 to 2014. Molecular identification of cryptic species of the C. parapsilosis complex was performed using polymerase chain reaction amplification of the gene encoding secondary alcohol dehydrogenase, followed by digestion with the restriction enzyme BanI. Minimum inhibitory concentrations were determined using the broth microdilution method according to European Committee for Antimicrobial Susceptibility Testing (EUCAST EDef 7.2) and Clinical Laboratory Standards Institute (CLSI M27-A3) guidelines, and the results were compared with those obtained using the E-test and Sensititre methods. Of the 163 C. parapsilosis complex isolates, 136 (83.4%) were identified as C. parapsilosis, and 27 (16.6%) as C. orthopsilosis. The species-specific incidences were 2.9/10,000 admissions for C. parapsilosis and 0.6/10,000 admissions for C. orthopsilosis. No resistance to echinocandins was detected with any of the methods. The percent essential agreement (EA) between the EUCAST and E-test/Sensititre methods for anidulafungin, caspofungin, and micafungin susceptibility was, respectively, as follows: C. parapsilosis, 95.6/97.8, 98.5/88.2, and 93.4/96.3; C. orthopsilosis, 92.6/92.6, 96.3/77.8, and 63.0/66.7. The EA between the CLSI and E-test/Sensititre methods was, respectively, as follows: C. parapsilosis, 99.3/100, 98.5/89.0, and 96.3/98.5; C. orthopsilosis, 96.3/92.6, 100/81.5, and 92.6/88.9. Only minor discrepancies, ranging from 16.9% (C. parapsilosis) to 11.1% (C. orthopsilosis), were observed between the CLSI and E-test/Sensititre methods. In conclusion, this epidemiologic study shows a typical C. parapsilosis complex species distribution, no echinocandin resistance, and it reinforces the relevance of using commercially available microbiological methods to assess antifungal susceptibility. These data improve our knowledge of the national distribution of species of the psilosis group, as there are very few studies of these species in Italy.

Citing Articles

Heterogeneity of bloodstream isolates in an academic medical center and affiliated hospitals.

Scott N, Wash E, Zajac C, Erayil S, Kline S, Selmecki A bioRxiv. 2025; .

PMID: 39975022 PMC: 11839140. DOI: 10.1101/2025.02.05.636768.


Investigation of clonal relationship in hospital-associated Candida parapsilosis isolates.

Ergon M, Gurbuz E, Arslan N, Alp S, Dereli M, Ozkutuk A Eur J Clin Microbiol Infect Dis. 2024; 44(2):311-322.

PMID: 39612138 DOI: 10.1007/s10096-024-04998-2.


Candida parapsilosis: A systematic review to inform the World Health Organization fungal priority pathogens list.

Asogan M, Kim H, Kidd S, Alastruey-Izquierdo A, Govender N, Dao A Med Mycol. 2024; 62(6).

PMID: 38935912 PMC: 11210616. DOI: 10.1093/mmy/myad131.


Echinocandins Susceptibility Patterns of 2,787 Yeast Isolates: Importance of the Thresholds for the Detection of FKS Mutations.

Desnos-Ollivier M, Bretagne S, Lortholary O, Dromer F Antimicrob Agents Chemother. 2022; 66(5):e0172521.

PMID: 35412354 PMC: 9116480. DOI: 10.1128/aac.01725-21.


A Pragmatic Approach to Susceptibility Classification of Yeasts without EUCAST Clinical Breakpoints.

Astvad K, Arikan-Akdagli S, Arendrup M J Fungi (Basel). 2022; 8(2).

PMID: 35205895 PMC: 8877802. DOI: 10.3390/jof8020141.


References
1.
Caggiano G, Coretti C, Bartolomeo N, Lovero G, De Giglio O, Montagna M . Candida Bloodstream Infections in Italy: Changing Epidemiology during 16 Years of Surveillance. Biomed Res Int. 2015; 2015:256580. PMC: 4439500. DOI: 10.1155/2015/256580. View

2.
Tavanti A, Davidson A, Gow N, Maiden M, Odds F . Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol. 2005; 43(1):284-92. PMC: 540126. DOI: 10.1128/JCM.43.1.284-292.2005. View

3.
Tumbarello M, Posteraro B, Trecarichi E, Fiori B, Rossi M, Porta R . Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J Clin Microbiol. 2007; 45(6):1843-50. PMC: 1933062. DOI: 10.1128/JCM.00131-07. View

4.
Odds F, Hanson M, Davidson A, Jacobsen M, Wright P, Whyte J . One year prospective survey of Candida bloodstream infections in Scotland. J Med Microbiol. 2007; 56(Pt 8):1066-1075. PMC: 2884937. DOI: 10.1099/jmm.0.47239-0. View

5.
Gomez-Lopez A, Alastruey-Izquierdo A, Rodriguez D, Almirante B, Pahissa A, Rodriguez-Tudela J . Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain. Antimicrob Agents Chemother. 2008; 52(4):1506-9. PMC: 2292570. DOI: 10.1128/AAC.01595-07. View